Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer
-
AstraZeneca to divest US Synagis rights to Sobi
-
US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review
-
Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial
-
Year-To-Date and Q3 2018 Results
-
Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
-
The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018
-
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
-
Phase III HARMONIZE Global trial of Lokelma confirms efficacy in maintaining normal potassium levels in Asian patients with hyperkalaemia
-
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
Latest articles and press releases
All of our latest press releases and articles are available to explore
